RU2013101996A - Диагностика и лечение рака молочной железы - Google Patents

Диагностика и лечение рака молочной железы Download PDF

Info

Publication number
RU2013101996A
RU2013101996A RU2013101996/15A RU2013101996A RU2013101996A RU 2013101996 A RU2013101996 A RU 2013101996A RU 2013101996/15 A RU2013101996/15 A RU 2013101996/15A RU 2013101996 A RU2013101996 A RU 2013101996A RU 2013101996 A RU2013101996 A RU 2013101996A
Authority
RU
Russia
Prior art keywords
ctc
treatment
tumor markers
course
determining
Prior art date
Application number
RU2013101996/15A
Other languages
English (en)
Other versions
RU2550925C2 (ru
Inventor
Дэниел ХЭЙЗ
Original Assignee
Зе Реджентс Оф Зе Юниверсити Оф Мичиган
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зе Реджентс Оф Зе Юниверсити Оф Мичиган filed Critical Зе Реджентс Оф Зе Юниверсити Оф Мичиган
Publication of RU2013101996A publication Critical patent/RU2013101996A/ru
Application granted granted Critical
Publication of RU2550925C2 publication Critical patent/RU2550925C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Databases & Information Systems (AREA)

Abstract

1. Способ определения курса лечения, включающийа) обнаружение уровня циркулирующих опухолевых клеток (ЦОК) в образце от субъекта с раком молочной железы; иб) определение курса лечения на основании указанного уровня ЦОК в указанном образце.2. Способ по п.1, отличающийся тем, что указанный курс лечения содержит анти-эстрогенную терапию.3. Способ по п.2, отличающийся тем, что, указанная анти-эстрогенная терапия включает тамоксифен.4. Способ по п.2, отличающийся тем, что указанную анти-эстрогенную терапию выбирают из группы, состоящей из летрозола, анастрозола и экземестана.5. Способ по п.1, отличающийся тем, что указанный курс лечения включает химиотерапию.6. Способ по п.1, отличающийся тем, что, что указанный способ дополнительно включает этап характеризации одного или более опухолевых маркеров на указанных ЦОК.7. Способ по п.6, отличающийся тем, что указанные опухолевые маркеры выбирают из группы, состоящей из рецептора эстрогена, HER-2, bcl-2, маркеров апоптоза и ki67.8. Способ по п.7, отличающийся тем, что указанный маркер апоптоза обнаруживают с использованием моноклонального антитела М30.9. Способ по п.7, отличающийся тем, что один или более из указанных опухолевых маркеров определяют с использованием способа множественной ПЦР.10. Способ по п.7, отличающийся тем, что указанные опухолевые маркеры обнаруживают с использованием иммуномагнитного анализа.11. Способ по п.6, отличающийся тем, что указанный способ дополнительно включает этап определения ЦОК - индекса эндокринной терапии (ЦОК-ИЭТ).12. Способ по п.11, отличающийся тем, что указанный ЦОК-ИЭТ основан на указанной экспрессии указанных опухолевых маркеров и общем количестве ЦОК.13. Сп�

Claims (14)

1. Способ определения курса лечения, включающий
а) обнаружение уровня циркулирующих опухолевых клеток (ЦОК) в образце от субъекта с раком молочной железы; и
б) определение курса лечения на основании указанного уровня ЦОК в указанном образце.
2. Способ по п.1, отличающийся тем, что указанный курс лечения содержит анти-эстрогенную терапию.
3. Способ по п.2, отличающийся тем, что, указанная анти-эстрогенная терапия включает тамоксифен.
4. Способ по п.2, отличающийся тем, что указанную анти-эстрогенную терапию выбирают из группы, состоящей из летрозола, анастрозола и экземестана.
5. Способ по п.1, отличающийся тем, что указанный курс лечения включает химиотерапию.
6. Способ по п.1, отличающийся тем, что, что указанный способ дополнительно включает этап характеризации одного или более опухолевых маркеров на указанных ЦОК.
7. Способ по п.6, отличающийся тем, что указанные опухолевые маркеры выбирают из группы, состоящей из рецептора эстрогена, HER-2, bcl-2, маркеров апоптоза и ki67.
8. Способ по п.7, отличающийся тем, что указанный маркер апоптоза обнаруживают с использованием моноклонального антитела М30.
9. Способ по п.7, отличающийся тем, что один или более из указанных опухолевых маркеров определяют с использованием способа множественной ПЦР.
10. Способ по п.7, отличающийся тем, что указанные опухолевые маркеры обнаруживают с использованием иммуномагнитного анализа.
11. Способ по п.6, отличающийся тем, что указанный способ дополнительно включает этап определения ЦОК - индекса эндокринной терапии (ЦОК-ИЭТ).
12. Способ по п.11, отличающийся тем, что указанный ЦОК-ИЭТ основан на указанной экспрессии указанных опухолевых маркеров и общем количестве ЦОК.
13. Способ по п.1, отличающийся тем, что указанный рак молочной железы является метастатическим.
14. Способ по п.1, отличающийся тем, что указанный рак молочной железы является положительным по рецептору эстрогена.
RU2013101996/15A 2010-07-07 2011-07-07 Диагностика и лечение рака молочной железы RU2550925C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36202110P 2010-07-07 2010-07-07
US61/362,021 2010-07-07
US201161469890P 2011-03-31 2011-03-31
US61/469,890 2011-03-31
PCT/US2011/043189 WO2012006421A2 (en) 2010-07-07 2011-07-07 Diagnosis and treatment of breast cancer

Publications (2)

Publication Number Publication Date
RU2013101996A true RU2013101996A (ru) 2014-08-20
RU2550925C2 RU2550925C2 (ru) 2015-05-20

Family

ID=45438858

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013101996/15A RU2550925C2 (ru) 2010-07-07 2011-07-07 Диагностика и лечение рака молочной железы

Country Status (11)

Country Link
US (3) US8790878B2 (ru)
EP (2) EP3306321A1 (ru)
JP (1) JP5951603B2 (ru)
CN (1) CN103109187B (ru)
AU (1) AU2011274789B2 (ru)
BR (1) BR112013000433A2 (ru)
CA (1) CA2804269A1 (ru)
DK (1) DK2591363T3 (ru)
ES (1) ES2652600T3 (ru)
RU (1) RU2550925C2 (ru)
WO (1) WO2012006421A2 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006421A2 (en) 2010-07-07 2012-01-12 The Regents Of The University Of Michigan Diagnosis and treatment of breast cancer
WO2012097820A1 (en) * 2011-01-20 2012-07-26 Syddansk Universitet Method and assay for predicting long-term efficacy of tamoxifen treatment in estrogen receptor-positive breast cancer patients
US20120252038A1 (en) * 2011-04-01 2012-10-04 Chianese David A Steroid receptor assays
BR112014018192A8 (pt) 2012-01-24 2021-03-02 Epic Sciences Inc método e kit para detecção de células tumorais circulantes 5t4-positivas, bem como métodos de diagnóstico de câncer 5t4-positivo e de seleção para atividade e eficácia de conjugado fármaco-anticorpo para tratamento de câncer
JP2016512197A (ja) * 2013-03-05 2016-04-25 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 間葉及び上皮間葉形質転換循環腫瘍細胞のための特異的検出ツール
AU2014333815B2 (en) * 2013-10-11 2020-07-09 Nihon University School Of Medicine Multiplex HER2 and estrogen receptor co-staining assays for detecting tumor heterogeneity
CN106456694B (zh) * 2013-12-20 2020-06-30 通用医疗公司 与循环肿瘤细胞相关的方法和测定法
WO2015093670A1 (ko) * 2013-12-20 2015-06-25 (주)옵티팜 조직 및 혈액을 이용한 유방암의 치료제 선별 검사 및 조기진단을 위한 역전사 정량적 중합효소연쇄반응 키트
JP6582486B2 (ja) * 2015-03-27 2019-10-02 コニカミノルタ株式会社 血液中の稀少細胞検出方法
CN104892759B (zh) * 2015-06-18 2018-04-03 福州迈新生物技术开发有限公司 由杂交瘤细胞系分泌的抗Ki67单克隆抗体及其应用
CN104991010B (zh) * 2015-07-29 2017-10-13 中国药科大学 一种区分乳腺癌亚型生物标志物的组合物
RU2641158C2 (ru) * 2016-02-03 2018-01-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Нижегородская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО НижГМА Минздрава России) Способ оценки эффективности неоадъювантной полихимиотерапии злокачественной опухоли молочной железы
RU2624367C1 (ru) * 2016-05-12 2017-07-03 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ выбора объема локорегионарной лучевой терапии после хирургической операции по поводу рака молочной железы
CN110225980B (zh) 2016-11-21 2023-01-06 纳米线科技公司 化学组合物及其使用方法
RU2637859C1 (ru) * 2017-02-13 2017-12-07 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Способ дифференцированного лечения больных локализованным раком молочной железы
KR20210061962A (ko) 2018-05-14 2021-05-28 나노스트링 테크놀로지스, 인크. 화학 조성물 및 이의 사용 방법
RU2706029C1 (ru) * 2018-10-09 2019-11-13 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения люминального подтипа рака молочной железы
CN111661161B (zh) 2020-06-08 2021-06-08 浙江联控技术有限公司 一种用于车辆的拖车装置及车辆
RU2760168C1 (ru) * 2021-02-05 2021-11-22 федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации Способ прогнозирования результатов лечения эмбриональных опухолей

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
ATE88761T1 (de) 1986-01-10 1993-05-15 Amoco Corp Kompetitiver homogener test.
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5283174A (en) 1987-09-21 1994-02-01 Gen-Probe, Incorporated Homogenous protection assay
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5225326A (en) 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
WO1991001384A1 (en) 1989-07-11 1991-02-07 Gen-Probe, Incorporated Nucleic acid sequence amplification methods utilizing a transcription complex
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5270184A (en) 1991-11-19 1993-12-14 Becton, Dickinson And Company Nucleic acid target generation
US5545524A (en) 1991-12-04 1996-08-13 The Regents Of The University Of Michigan Compositions and methods for chromosome region-specific probes
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
JP3189000B2 (ja) 1994-12-01 2001-07-16 東ソー株式会社 特定核酸配列の検出方法
US5710029A (en) 1995-06-07 1998-01-20 Gen-Probe Incorporated Methods for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product
US6121489A (en) 1996-03-05 2000-09-19 Trega Biosciences, Inc. Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein
JP3898228B2 (ja) 1996-04-12 2007-03-28 ザ パブリック ヘルス リサーチ インスティチュート オブ ザ シティー オブ ニューヨーク インク 検出プローブ、キット及びアッセイ
US20020172987A1 (en) * 1998-02-12 2002-11-21 Terstappen Leon W.M.M. Methods and reagents for the rapid and efficient isolation of circulating cancer cells
ATE440963T1 (de) 1998-07-02 2009-09-15 Gen Probe Inc Molekulare fackeln
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
US6303305B1 (en) 1999-03-30 2001-10-16 Roche Diagnostics, Gmbh Method for quantification of an analyte
DE60014762T2 (de) 1999-05-24 2005-10-13 Tosoh Corp., Shinnanyo Methode zum Nachweis von Ribonukleinsäuren
JP2005516217A (ja) * 2001-02-16 2005-06-02 イムニベスト・コーポレイション 循環している癌細胞の急速かつ効果的な単離のための方法および試薬
US7863012B2 (en) * 2004-02-17 2011-01-04 Veridex, Llc Analysis of circulating tumor cells, fragments, and debris
ES2268387T3 (es) * 2002-03-13 2007-03-16 Biomerieux Procedimiento de deteccion y de cuantificacion de celulas tumorales circulantes, procedentes de canceres solidos.
EP1400806A1 (en) 2002-09-18 2004-03-24 G2M Cancer Drugs AG The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity
JP4593557B2 (ja) * 2003-02-27 2010-12-08 ベリデックス・リミテッド・ライアビリティ・カンパニー 循環腫瘍細胞（ｃｔｃ）：転移癌患者における増悪までの時間、生存および療法に対する応答の早期評価
EP1618215A4 (en) 2003-05-01 2007-12-05 Gen Probe Inc OLIGONUCLEOTIDE AS MOLECULAR SWITCH
CA2980050C (en) 2004-08-27 2018-01-23 Gen-Probe Incorporated Single-primer nucleic acid amplification methods
WO2006041959A2 (en) * 2004-10-06 2006-04-20 Wellstat Biologics Corporation Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment
US20090118175A1 (en) * 2005-05-06 2009-05-07 Macina Roberto A Compositions and Methods for Detection, Prognosis and Treatment of Breast Cancer
US20080275652A1 (en) * 2005-05-13 2008-11-06 Universite Libre De Bruxelles Gene-based algorithmic cancer prognosis
US20070037173A1 (en) * 2005-08-12 2007-02-15 Allard Jeffrey W Circulating tumor cells (CTC's): early assessment of time to progression, survival and response to therapy in metastatic cancer patients
US20080038725A1 (en) * 2005-06-20 2008-02-14 Yuling Luo Methods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations
US20070071762A1 (en) 2005-09-21 2007-03-29 Ccc Diagnostics, Llc Comprehensive diagnostic testing procedures for personalized anticancer chemotherapy (pac)
WO2007089911A2 (en) * 2006-01-30 2007-08-09 The Scripps Research Institute Methods for detection of circulating tumor cells and methods of diagnosis of cancer in a mammalian subject
US20070231822A1 (en) * 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer
CA2647743A1 (en) * 2006-04-18 2007-10-25 Wellstat Biologics Corporation Detection of steroid receptors on circulating carcinoma cells and treatment
US20080113350A1 (en) * 2006-11-09 2008-05-15 Terstappen Leon W M M Blood test to monitor the genetic changes of progressive cancer using immunomagnetic enrichment and fluorescence in situ hybridization (FISH)
EP2155905A1 (en) * 2007-05-31 2010-02-24 Dako Denmark A/S Methods for utilizing esr copy number changes in breast cancer treatments and prognoses
US20090061456A1 (en) * 2007-08-30 2009-03-05 Allard William J Method for predicting progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients using circulating tumor cells
DK2602623T3 (en) * 2008-02-25 2015-11-09 Nestec Sa METHOD OF DETECTING INTRACELLULAR TRUNCTED RECEPTORS
US20130178383A1 (en) * 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
WO2011109440A1 (en) * 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
US20100311601A1 (en) * 2009-05-01 2010-12-09 Nuvera Biosciences, Inc. Index of genomic expression of estrogen receptor (er) and er-related genes
WO2011127219A1 (en) * 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
WO2012006421A2 (en) 2010-07-07 2012-01-12 The Regents Of The University Of Michigan Diagnosis and treatment of breast cancer

Also Published As

Publication number Publication date
DK2591363T3 (en) 2017-12-11
CN103109187A (zh) 2013-05-15
CA2804269A1 (en) 2012-01-12
BR112013000433A2 (pt) 2016-05-17
CN103109187B (zh) 2015-03-25
WO2012006421A2 (en) 2012-01-12
WO2012006421A3 (en) 2012-04-26
US8790878B2 (en) 2014-07-29
JP2013533486A (ja) 2013-08-22
US9568476B2 (en) 2017-02-14
EP3306321A1 (en) 2018-04-11
US20140295444A1 (en) 2014-10-02
ES2652600T3 (es) 2018-02-05
AU2011274789B2 (en) 2014-04-10
EP2591363A4 (en) 2014-01-22
US10677801B2 (en) 2020-06-09
JP5951603B2 (ja) 2016-07-13
US20120009582A1 (en) 2012-01-12
US20170242011A1 (en) 2017-08-24
AU2011274789A1 (en) 2013-01-24
RU2550925C2 (ru) 2015-05-20
EP2591363B1 (en) 2017-09-20
EP2591363A2 (en) 2013-05-15

Similar Documents

Publication Publication Date Title
RU2013101996A (ru) Диагностика и лечение рака молочной железы
D'Alfonso et al. Axl receptor tyrosine kinase expression in breast cancer
Lee et al. SOX2 regulates self-renewal and tumorigenicity of stem-like cells of head and neck squamous cell carcinoma
McCullough et al. Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study
Healey et al. Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses’ Health Study
Mendelsohn et al. Snail as a novel marker for regional metastasis in head and neck squamous cell carcinoma
Zhang et al. Linc00152 promotes cancer cell proliferation and invasion and predicts poor prognosis in lung adenocarcinoma
Kim et al. The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients
EA201691352A1 (ru) Диагностика рака легкого с помощью циркулирующих опухолевых клеток
Falck et al. Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study
WO2011112903A3 (en) Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients
Matsumoto et al. HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or paraaortic) metastasis (JCOG1005-A trial)
Shi et al. Dickkopf-1 is a novel prognostic biomarker for laryngeal squamous cell carcinoma
Egevad et al. Beta-tubulin III expression in prostate cancer
Liu et al. Overexpression of LncRNA PVT1 predicts advanced clinicopathological features and serves as an unfavorable risk factor for survival of patients with gastrointestinal cancers
Gavid et al. Human papillomavirus and head and neck squamous cell carcinomas in the South-East of France: prevalence, viral expression, and prognostic implications
Kaprin et al. The cervical cancer screening-unsolved problems
EA201891085A1 (ru) Получение геномных профилей отдельных клеток для циркулирующих клеток опухолей (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания
Asproni et al. Immunohistochemical expression of cyclooxygenase-2 in normal, hyperplastic and neoplastic canine lymphoid tissues
Synnestvedt et al. Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome
RU2013135809A (ru) Способ прогнозирования эффективности химиотерапии у больных со злокачественными новообразованиями эпителиальных тканей
Jiang et al. SPARC and Vav3 expression in meningioma: factors related to prognosis
Albarracin et al. Evolving role of Ki67 as a predictive and prognostic marker in breast cancer
ZOU The mechanism of microRNA-29b regulating cyclin D2 expression in the genesis of human cervical cancer
Rath Molecular markers in the head and neck cancers: Are we there yet?